David T. Rubin

34.1k total citations · 9 hit papers
727 papers, 18.1k citations indexed

About

David T. Rubin is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, David T. Rubin has authored 727 papers receiving a total of 18.1k indexed citations (citations by other indexed papers that have themselves been cited), including 524 papers in Genetics, 406 papers in Epidemiology and 210 papers in Surgery. Recurrent topics in David T. Rubin's work include Inflammatory Bowel Disease (520 papers), Microscopic Colitis (354 papers) and Eosinophilic Esophagitis (74 papers). David T. Rubin is often cited by papers focused on Inflammatory Bowel Disease (520 papers), Microscopic Colitis (354 papers) and Eosinophilic Esophagitis (74 papers). David T. Rubin collaborates with scholars based in United States, Canada and United Kingdom. David T. Rubin's co-authors include Corey A. Siegel, Ruben J. Colman, Russell D. Cohen, Ashwin N. Ananthakrishnan, Millie D. Long, Bryan G. Sauer, Silvio Danese, Jerrold R. Turner, Joel Pekow and William J. Sandborn and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

David T. Rubin

661 papers receiving 17.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

2021 1.5k citations William J. Sandborn, Bruce E. Sands et al. Gastroenterology profile →
ACG Clinical Guideline: Ulcerative Colitis in Adults

2019 1.0k citations David T. Rubin, Ashwin N. Ananthakrishnan et al. profile →
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management

2021 480 citations David T. Rubin et al. Gastroenterology profile →
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

2015 437 citations David T. Rubin et al. Gastroenterology profile →
Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis

2014 356 citations David T. Rubin et al. Journal of Crohn s and Colitis profile →
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

2017 328 citations David T. Rubin et al. Journal of Crohn s and Colitis profile →
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation

2019 313 citations David T. Rubin et al. Inflammatory Bowel Diseases profile →
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

2022 132 citations William J. Sandborn, Matthew Germinaro et al. Gastroenterology profile →
What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?

2022 123 citations Noa Krugliak Cleveland, David T. Rubin et al. Gastroenterology profile →

Peers

Countries citing papers authored by David T. Rubin

Since Specialization

Citations

This map shows the geographic impact of David T. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Rubin more than expected).

Fields of papers citing papers by David T. Rubin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Rubin. The network helps show where David T. Rubin may publish in the future.

Co-authorship network of co-authors of David T. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Rubin. A scholar is included among the top collaborators of David T. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Rubin. David T. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A practical approach to positioning therapies in ulcerative colitis 2025 ·Journal of the Canadian Association of Gastroenterology ·(unknown), David T. Rubin	1
2	P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study 2025 ·Journal of Crohn s and Colitis ·Siddharth Sridhar, (unknown), (unknown), (unknown), Shadi Yarandi, Matthew Germinaro, (unknown), David T. Rubin, Axel Dignaß, (unknown), Tom C. Freeman, Dawn Waterworth, Bradford L. McRae, (unknown), Patrick Branigan	0
3	Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series 2025 ·Digestive Diseases and Sciences ·(unknown), David Choi, Andrew Aronsohn, Anjana Pillai, Russell D. Cohen, David T. Rubin	0
4	DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme 2025 ·Journal of Crohn s and Colitis ·Séverine Vermeire, David T. Rubin, Miguel Regueiro, Ken Takeuchi, Alissa Walsh, Paulo Gustavo Kotze, (unknown), Martina Goetsch, (unknown), Joseph Wu, (unknown), (unknown), (unknown), Silvio Danese	0
5	P0638 Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study 2025 ·Journal of Crohn s and Colitis ·B E Sands, (unknown), David T. Rubin, Stefan Schreiber, Corey A. Siegel, Andrés Yarur, Silvio Danese, Angray S. Kang, (unknown), (unknown), Stephen B. Hanauer	0
6	P1057 Upadacitinib as Salvage Therapy for Acute Severe Ulcerative Colitis: A Single-Center Experience 2024 ·Journal of Crohn s and Colitis ·(unknown), Dong Gyu Choi, Noa Krugliak Cleveland, (unknown), (unknown), (unknown), (unknown), Elise Fear, (unknown), Jiho Han, (unknown), David T. Rubin	0
7	Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 2024 ·Inflammatory Bowel Diseases ·Mohammad Zamani, (unknown), Shaghayegh Alizadeh‐Tabari, Scott E. Kasner, Mitchell S.V. Elkind, Ashwin N. Ananthakrishnan, (unknown), David T. Rubin, Reza Malekzadeh	11
8	Refining estimation of the instantaneous reproduction number during early pandemic stages: addressing case-reporting variability and serial interval uncertainty 2024 ·American Journal of Epidemiology ·(unknown), David T. Rubin, Jing Huang	1
9	OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics 2023 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, (unknown), (unknown), Jesse Siffledeen, (unknown), Efrat Broide, (unknown), Ana P. Lacerda, (unknown), (unknown), Sjoerd A.A. van den Berg, David T. Rubin	4
10	Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY 2023 ·Inflammatory Bowel Diseases ·Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, Tim Bancroft, (unknown), Tao Fan, (unknown), David T. Rubin	9
11	Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme 2023 ·Journal of Crohn s and Colitis ·Tim Raine, Yoh Ishiguro, David T. Rubin, Tricia Finney‐Hayward, (unknown), John Liu, Charles M. Phillips, (unknown), Laura E. Targownik, Edward V. Loftus	4
12	477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1 2023 ·Gastroenterology ·Bruce E. Sands, Laurent Peyrin‐Biroulet, Silvio Danese, David T. Rubin, Séverine Vermeire, Christopher Ma, Timothy E. Ritter, Remo Panaccione, Brian G. Feagan, Dermot McGovern, Olivier Laurent, Allison Luo, Deanna D. Nguyen, (unknown), Anna Wiechowska–Kozłowska, Jarosław Leszczyszyn, Radosław Kempiński, Jarosław Kierkuś, Stephan R. Targan	1
13	P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme 2023 ·Journal of Crohn s and Colitis ·Séverine Vermeire, Andrés Yarur, David T. Rubin, Marla C. Dubinsky, Miguel Regueiro, Peter M. Irving, Laurent Peyrin‐Biroulet, (unknown), (unknown), Joseph Wu, Irene Modesto, (unknown), (unknown), (unknown), (unknown)	3
14	P580 Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience 2023 ·Journal of Crohn s and Colitis ·(unknown), D Choi, (unknown), (unknown), Nicole Garcia, (unknown), Nathaniel A. Cohen, R D Cohen, Sushila Dalal, Joel Pekow, Atsushi Sakuraba, Noa Krugliak Cleveland, David T. Rubin	0
15	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes 2020 ·Journal of Crohn s and Colitis ·Britt Christensen, Stephen B. Hanauer, Peter G. Gibson, Jerrold R. Turner, John Hart, David T. Rubin	12
16	Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS 2020 ·Gastroenterology ·David T. Rubin, Marla C. Dubinsky, Silvio Danese, Rogério Saad-Hossne, Darío Ponce de León, Eric S. Maller, Nervin Lawendy, Kenneth Kwok, Chinyu Su	1
17	miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD 2017 ·Clinical Cancer Research ·Joel Pekow, Katherine Meckel, Urszula Dougherty, Yong Huang, Xindi Chen, (unknown), Reba Mustafi, (unknown), Zifeng Deng, (unknown), John Hart, David T. Rubin, John H. Kwon, Marc Bissonnette	72
18	OP011. Budesonide MMX(R) 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs 2015 ·Journal of Crohn s and Colitis ·David T. Rubin, Russell D. Cohen, William J. Sandborn, Gary R. Lichtenstein, Jeffrey Axler, Robert H. Riddell, Chen Zhu, A. M. Barrett, Enoch Bortey, William P. Forbes	7
19	P506. Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic factors 2015 ·Journal of Crohn s and Colitis ·B G Feagan, David A. Schwartz, Silvio Danese, David T. Rubin, (unknown), Michael Smyth, Jing Xu, Karen Lasch, (unknown), (unknown)	1
20	P353. Are we under-recognizing skewed thiopurine metabolism in IBD patients? Routine thiopurine metabolite measurement yields clinical benefit at 12 months: A retrospective observational study. 2015 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Rachel Grafton, Paul Leach, (unknown), Watson Ng, Susan J. Connor, Peter A. Bampton, Jane M. Andrews, David T. Rubin, Martha Skup, Scott J. Johnson, J. Chao, Allan Gibofsky, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact